3-{5-[3-Ethyl-4-oxo-2-thioxo-thiazolidin-(5Z)-ylidenemethyl]-furan-2-yl}-thiophene-2-carboxylic acid methyl ester

ID: ALA150886

PubChem CID: 44366838

Max Phase: Preclinical

Molecular Formula: C16H13NO4S3

Molecular Weight: 379.48

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCN1C(=O)/C(=C/c2ccc(-c3ccsc3C(=O)OC)o2)SC1=S

Standard InChI:  InChI=1S/C16H13NO4S3/c1-3-17-14(18)12(24-16(17)22)8-9-4-5-11(21-9)10-6-7-23-13(10)15(19)20-2/h4-8H,3H2,1-2H3/b12-8-

Standard InChI Key:  WCQHNBIGYHCYAX-WQLSENKSSA-N

Molfile:  

     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   -1.9458    1.3583    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6875    0.5708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6083    1.3583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2750    1.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6250   -0.9000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8625    0.5708    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.3750   -1.2292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4542   -0.0917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1792    1.6083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7000    0.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7875    1.0583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0875   -0.8167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0042    0.5125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2917   -2.0500    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1750   -0.0917    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.5917    1.2333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0792   -1.5042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4875   -2.2167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2833    2.6625    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0875    0.0083    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7250    1.6083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8042   -1.2292    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5167   -0.8125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9000    2.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  4  1  0
  4  1  1  0
  5  8  1  0
  6  2  1  0
  7  5  2  0
  8 10  1  0
  9  3  2  0
 10 11  1  0
 11  9  1  0
 12  7  1  0
 13 16  1  0
 14  7  1  0
 15  2  2  0
 16 11  2  0
 17  5  1  0
 18 17  2  0
 19  4  2  0
 20 12  2  0
 21  1  1  0
 22 12  1  0
 23 22  1  0
 24 21  1  0
  3  6  1  0
 13  8  2  0
 14 18  1  0
M  END

Associated Targets(Human)

TNFRSF1A Tchem Tumor necrosis factor receptor R1 (157 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 379.48Molecular Weight (Monoisotopic): 379.0007AlogP: 4.02#Rotatable Bonds: 4
Polar Surface Area: 59.75Molecular Species: NEUTRALHBA: 7HBD:
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: 3.86CX LogD: 3.86
Aromatic Rings: 2Heavy Atoms: 24QED Weighted: 0.45Np Likeness Score: -2.03

References

1. Voss ME, Carter PH, Tebben AJ, Scherle PA, Brown GD, Thompson LA, Xu M, Lo YC, Yang G, Liu RQ, Strzemienski P, Everlof JG, Trzaskos JM, Decicco CP..  (2003)  Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonists.,  13  (3): [PMID:12565966] [10.1016/s0960-894x(02)00941-1]

Source